Repros Therapeutics Inc (RPRX)

[akasidney86]

I think it's readily a trade-of with Costs.

I disagree. I don't know why there would be so much concern about the size of the trial given that RPRX management has the data it needs to make that decision, and they've decided that 15-17 in the smaller arm is sufficient to drive the results they're looking for. I don't think that the cost vs. desired results argument works in this case simply because we're not talking about assuming the increased costs of taking 100 to 200, or 200 to 500... those numbers would indeed represent real money that could sway a decision to the smaller numbers. In this case, lets say that they had doubts and considered doubling the size of the trial to really power it with the degree of comfort they'd like... we're talking about increasing it in absolute terms by 15 people (per), and that just doesn't represent a whole lot of money. Therefore, common sense tells me that the decision of how many patients they decided upon was not made on economic, but rather statistical grounds, and isn't something that, if their biostats guys know what they're doing (and why wouldn't they)the trial is much more likely than not well powered.